Premium
Time course of 75%–100% efficacy response of adjunctive brivaracetam
Author(s) -
Klein Pavel,
Laloyaux Cédric,
Elmoufti Sami,
Gasalla Teresa,
Martin Melinda S.
Publication year - 2020
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.13287
Subject(s) - epilepsy , medicine , placebo , anesthesia , adjunctive treatment , randomized controlled trial , psychiatry , pathology , alternative medicine
Background Time to sustained seizure frequency reduction can provide clinically meaningful epilepsy outcomes. Aims of the Study To examine the time course of brivaracetam (BRV) efficacy in adults with focal seizures and focal to bilateral tonic‐clonic seizures (FBTCS). Methods Post hoc analysis of data pooled from three randomized controlled trials of oral adjunctive BRV in adults with epilepsy. Patients with focal epilepsy and a subpopulation with FBTCS receiving BRV 50, 100, or 200 mg/d (initiated without up‐titration) or placebo for 12 weeks were analyzed for time to sustained ≥75%, ≥90%, and 100% seizure reduction without interruption from first day until trial ends. Results Evaluation included 1160 patients with focal seizures, including 352 patients with FBTCS. Sustained ≥75%, ≥90%, and 100% response in focal seizures was higher from day 1 for BRV 100 and 200 mg/d vs placebo ( P < .01). Sustained ≥75% and 100% FBTCS reduction from day 1 was higher for BRV 100 and 200‐mg/d groups vs placebo ( P < .01). Conclusions The majority of patients achieving 75%‐100% sustained seizure frequency reduction (all focal seizure types and the subpopulation with FBTCS) with oral BRV (100 or 200 mg/d) achieved this response on the first‐treatment day.